District Modality Leader - Sales, Magnetic Resonance
About the job
- At least 5 years of success in healthcare sales, imaging, or clinical technology leadership, ideally within diagnostic imaging or Magnetic Resonance.
- A proven track record of exceeding sales targets in a complex, long-cycle, team-selling environment.
- Ability to influence and lead cross-functional teams without direct authority while driving accountability and results.
- Strong business acumen and the ability to translate clinical and technical expertise into customer value.
- A Bachelor's degree in a relevant field or equivalent education and experience.
- Ability to successfully perform the minimum physical, cognitive, and environmental job requirements for the Sales position with or without accommodation.
- High organization and data-driven working style, with experience using Salesforce and PowerBI for forecasting and pipeline management.
- Ability to manage multiple priorities across a large territory and travel extensively.
- Own the Magnetic Resonance business for the district, driving orders, revenue growth, market share, and margin performance.
- Develop and execute district- and territory-level Magnetic Resonance growth strategies tailored to competitive dynamics and customer needs.
- Partner with Imaging Account Managers and District Sales Leaders to advance opportunities, strengthen account plans, and close complex deals.
- Act as the district's Magnetic Resonance expert, providing clinical, technical, and competitive guidance to sales teams and customers.
- Coach and develop field teams through joint customer engagements, pipeline reviews, and strategic deal support.
- Leverage data, forecasting, and market intelligence to improve visibility, prioritize opportunities, and optimize commercial execution.
- Experience in diagnostic imaging or Magnetic Resonance is preferred.
About the company
Philips makes medical equipment and software for hospitals and care providers, along with personal health products for consumers. Its hospital portfolio spans MRI and CT scanners, ultrasound, image-guided treatment systems and patient monitors, while Sonicare and Avent cover oral health and baby care. Clinical software connects medical images and patient data across care teams, and the company earns revenue from equipment, software, maintenance and consumer product sales. It works with health systems through long-term technology and service partnerships, including solutions for care at home. Founded in 1891, Philips is headquartered in Amsterdam, the Netherlands.
Company Size
10,001+
Company Stage
Acquired
Total Funding
$164.7M
Headquarters
Murrysville, Pennsylvania
Founded
1891
Get referred to Philips
See people who can refer or advise you
Simplify's Take
What believers are saying
- Demand improved: Philips reported 4% comparable group sales growth for Q2 2026 in July 2026.
- Software expertise has room to develop: software and data science comprised about half Philips' research effort in 2025.
- Manufacturing expansion has backing: Philips reiterated a $150 million North American investment plan in February 2026.
What critics are saying
- US sleep-device sales remain restricted: Philips Respironics must meet consent-decree requirements before resuming new sleep-therapy device sales.
- Underlying earnings weakened: Philips' July 2026 report shows Q2 adjusted earnings fell slightly excluding its US tariff refund.
- Central teams face cost pressure: February 2026 plans target 15% to 20% lower central-function costs at Philips.
What makes Philips unique
- MRI avoids helium refills: Philips says its sealed BlueSeal magnets use seven liters rather than conventional systems' 1,500.
- Inventions form a substantial asset base: Philips reports 53,000 patent rights across its technology portfolio.
- The employer's name spans independent businesses: Philips licenses its brands across multiple product categories to outside partners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.